| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3406647 | Journal of Virological Methods | 2013 | 6 Pages |
•Two HIV-1 viral load assays were evaluated using the same samples.•These assays showed a strong correlation and were in agreement of 94.4%.•The VQA template has an application for validating other viral load assays.•Abbott HIV-1 RealTime™ assay has features like higher analytical sensitivity.•Abbott HIV-1 RealTime™ assay also has capacity to amplify a plethora of pathogens.
The implementation of cost effective HIV-1 viral load assays in resource-limited settings have been an impediment for monitoring HIV-1 therapy. A study involving the comparative analytical performance of two HIV-1 viral load assays – Standard Roche COBAS® Amplicor™ HIV-1 Monitor® Test, version 1.5 (Roche Diagnostics, Basel, Switzerland) and Abbott HIV-1 RealTime™ assay (Abbott Molecular, Wiesbaden, Germany) was performed using 125 specimens in Pune, India. A strong correlation was observed between the manual endpoint reverse transcriptase polymerase chain reaction assay and the recent real time polymerase chain reaction assay (r = 0.989, p value < 0.0001) and agreement was 94.4%. Results of the study indicate a higher sensitivity of the Abbott HIV-1 RealTime™ assay for HIV-1 Virology Quality Assurance copy controls as compared to the Standard Roche COBAS® Amplicor™ HIV-1 Monitor® Test, version 1.5. Furthermore, features of the Abbott m2000rt RealTime™ PCR assay platform such as higher analytical sensitivity, automated/manual extraction platforms for high/low sample throughputs and ability to quantify a variety of infectious agents (Hepatitis B virus, Hepatitis C virus, Human Papillomavirus and Neisseria gonorrhoeae/Chlamydia trachomatis) justify its suitability in resource-limited Indian settings. Besides, the study also highlights utility of the precise Virology Quality Assurance validation template in performance evaluation of various quantitative viral load assays.
